Genomics4S

As genomic technologies move from treating disease to selecting future individuals, definitions of disease cease to function exclusively as medical categories and become social decisions about which traits and what kinds of people should exist.

While the recent adoption of a flexible clinical translation model in Hainan Province promises to accelerate biomedical innovation in China, it has also intensified concerns about patient safety, transparency, and misinformation. The success of this new approach is largely dependent on strengthening post-market oversight, access to clinical data, and strategic alignment with international bioethical guidelines.

The ability to reduce the burden of genetic disease is one of the most compelling promises of genomic medicine. But the path forward for embryo selection and gene editing is not purely technical; it demands rigorous evaluation of scientific evidence, sustained ethical reflection, and broad public consensus.

India's largely unregulated market for personalized medicine services desperately needs regulation and public accountability....